School of Pharmacy, Changzhou University, Changzhou 213164, China.
Department of Pharmacy, Wujin Hospital Affiliated with Jiangsu University, Changzhou 213000, China; The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, China.
Eur J Pharm Biopharm. 2024 Sep;202:114409. doi: 10.1016/j.ejpb.2024.114409. Epub 2024 Jul 10.
In this study, a novel approach was employed to develop a therapeutic system for colorectal cancer treatment. Specifically, a GelMA/SilMA hydrogel loaded with curcumin-shellac nanoparticles (Cur@Lac NPs) was created. A microfluidic swirl mixer was utilized to formulate stable Cur@Lac NPs, ensuring their consistent and effective encapsulation. The pH-specific release of curcumin from the NPs demonstrated their potential for colon cancer treatment. By carefully regulating the ratio of GelMA (gelatin methacrylate) and SilMA (silk fibroin methacrylate), a GelMA/SilMA dual network hydrogel was generated, offering controlled release and degradation capabilities. The incorporation of SilMA notably enhanced the mechanical properties of the dual network matrix, improving compression resistance and mitigating deformation. This mechanical improvement is crucial for maintaining the structural integrity of the hydrogel during in vivo applications. In comparison to the direct incubation of curcumin, the strategy of encapsulating curcumin into NPs and embedding them within the GelMA/SilMA hydrogel resulted in more controlled release mechanisms. This controlled release was achieved through the disintegration of the NPs and the swelling and degradation of the hydrogel matrix. The encapsulating strategy also demonstrated enhanced cellular uptake of curcumin, leveraging the advantages of both NPs and in-situ hydrogel injection. This combination ensures a more efficient and sustained delivery of the therapeutic agent directly to the tumor site. Overall, this approach holds significant promise as a smart drug delivery system, potentially improving the efficacy of colorectal cancer treatments by providing targeted, controlled, and sustained drug release with enhanced mechanical stability and biocompatibility.
在这项研究中,采用了一种新方法来开发用于结直肠癌治疗的治疗系统。具体来说,创建了负载姜黄素-壳聚糖纳米粒子(Cur@Lac NPs)的 GelMA/SilMA 水凝胶。使用微流旋混合器来配制稳定的 Cur@Lac NPs,确保其有效的包封。纳米粒子中姜黄素的 pH 特异性释放表明其在结肠癌治疗中的潜力。通过仔细调节 GelMA(明胶甲基丙烯酰胺)和 SilMA(丝素甲基丙烯酰胺)的比例,生成了 GelMA/SilMA 双网络水凝胶,提供了可控的释放和降解能力。SilMA 的掺入显著增强了双网络基质的机械性能,提高了抗压强度并减轻了变形。这种机械性能的改善对于在体内应用中保持水凝胶的结构完整性至关重要。与直接孵育姜黄素相比,将姜黄素封装成纳米粒子并嵌入 GelMA/SilMA 水凝胶中的策略导致了更可控的释放机制。这种控制释放是通过纳米粒子的崩解和水凝胶基质的溶胀和降解来实现的。封装策略还显示出增强的姜黄素细胞摄取,利用了纳米粒子和原位水凝胶注射的优势。这种组合确保了治疗剂更有效地和持续地递送到肿瘤部位。总的来说,这种方法作为一种智能药物递送系统具有重要的应用前景,通过提供靶向、可控和持续的药物释放,同时增强机械稳定性和生物相容性,有可能提高结直肠癌治疗的疗效。